252 related articles for article (PubMed ID: 26506619)
1. Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.
Havranek O; Kleiblova P; Hojny J; Lhota F; Soucek P; Trneny M; Kleibl Z
PLoS One; 2015; 10(10):e0140819. PubMed ID: 26506619
[TBL] [Abstract][Full Text] [Related]
2. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
3. Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma.
Havranek O; Spacek M; Hubacek P; Mocikova H; Markova J; Trneny M; Kleibl Z
Neoplasma; 2011; 58(5):392-5. PubMed ID: 21744992
[TBL] [Abstract][Full Text] [Related]
4. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.
Liu Y; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
BMC Cancer; 2015 Mar; 15():194. PubMed ID: 25884806
[TBL] [Abstract][Full Text] [Related]
5. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
[TBL] [Abstract][Full Text] [Related]
6. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
Cybulski C; Wokołorczyk D; Kładny J; Kurzawski G; Suchy J; Grabowska E; Gronwald J; Huzarski T; Byrski T; Górski B; D Ecedil Bniak T; Narod SA; Lubiński J
Eur J Hum Genet; 2007 Feb; 15(2):237-41. PubMed ID: 17106448
[TBL] [Abstract][Full Text] [Related]
7. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.
Stolarova L; Kleiblova P; Zemankova P; Stastna B; Janatova M; Soukupova J; Achatz MI; Ambrosone C; Apostolou P; Arun BK; Auer P; Barnard M; Bertelsen B; ; Blok MJ; Boddicker N; Brunet J; Burnside ES; Calvello M; Campbell I; Chan SH; Chen F; Chiang JB; Coppa A; Cortesi L; Crujeiras-González A; ; De Leeneer K; De Putter R; DePersia A; Devereux L; Domchek S; Efremidis A; Engel C; Ernst C; Evans DGR; Feliubadaló L; Fostira F; Fuentes-Ríos O; Gómez-García EB; González S; Haiman C; Hansen TVO; Hauke J; Hodge J; Hu C; Huang H; Ishak NDB; Iwasaki Y; Konstantopoulou I; Kraft P; Lacey J; Lázaro C; Li N; Lim WK; Lindstrom S; Lori A; Martinez E; Martins A; Matsuda K; Matullo G; McInerny S; Michailidou K; Montagna M; Monteiro ANA; Mori L; Nathanson K; Neuhausen SL; Nevanlinna H; Olson JE; Palmer J; Pasini B; Patel A; Piane M; Poppe B; Radice P; Renieri A; Resta N; Richardson ME; Rosseel T; Ruddy KJ; Santamariña M; Dos Santos ES; Teras L; Toland AE; Trentham-Dietz A; Vachon CM; Volk AE; Weber-Lassalle N; Weitzel JN; Wiesmuller L; Winham S; Yadav S; Yannoukakos D; Yao S; Zampiga V; Zethoven M; Zhang ZW; Zima T; Spurdle AB; Vega A; Rossing M; Del Valle J; De Nicolo A; Hahnen E; Claes KBM; Ngeow J; Momozawa Y; James PA; Couch FJ; Macurek L; Kleibl Z
Clin Cancer Res; 2023 Aug; 29(16):3037-3050. PubMed ID: 37449874
[TBL] [Abstract][Full Text] [Related]
8. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer.
Złowocka E; Cybulski C; Górski B; Debniak T; Słojewski M; Wokołorczyk D; Serrano-Fernández P; Matyjasik J; van de Wetering T; Sikorski A; Scott RJ; Lubiński J
Int J Cancer; 2008 Feb; 122(3):583-6. PubMed ID: 17918154
[TBL] [Abstract][Full Text] [Related]
9. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma.
Wang SS; Davis S; Cerhan JR; Hartge P; Severson RK; Cozen W; Lan Q; Welch R; Chanock SJ; Rothman N
Carcinogenesis; 2006 Sep; 27(9):1828-34. PubMed ID: 16543247
[TBL] [Abstract][Full Text] [Related]
11. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
12.
Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut.
Shen M; Zheng T; Lan Q; Zhang Y; Zahm SH; Wang SS; Holford TR; Leaderer B; Yeager M; Welch R; Kang D; Boyle P; Zhang B; Zou K; Zhu Y; Chanock S; Rothman N
Hum Genet; 2006 Jul; 119(6):659-68. PubMed ID: 16738949
[TBL] [Abstract][Full Text] [Related]
14. Survival from breast cancer in patients with CHEK2 mutations.
Huzarski T; Cybulski C; Wokolorczyk D; Jakubowska A; Byrski T; Gronwald J; Domagała P; Szwiec M; Godlewski D; Kilar E; Marczyk E; Siołek M; Wiśniowski R; Janiszewska H; Surdyka D; Sibilski R; Sun P; Lubiński J; Narod SA
Breast Cancer Res Treat; 2014 Apr; 144(2):397-403. PubMed ID: 24557336
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
Kriege M; Jager A; Hollestelle A; Berns EM; Blom J; Meijer-van Gelder ME; Sieuwerts AM; van den Ouweland A; Collée JM; Kroep JR; Martens JW; Hooning MJ; Seynaeve C
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1879-87. PubMed ID: 25958056
[TBL] [Abstract][Full Text] [Related]
16. Association of two mutations in the CHEK2 gene with breast cancer.
Bogdanova N; Enssen-Dubrowinskaja N; Feshchenko S; Lazjuk GI; Rogov YI; Dammann O; Bremer M; Karstens JH; Sohn C; Dörk T
Int J Cancer; 2005 Aug; 116(2):263-6. PubMed ID: 15810020
[TBL] [Abstract][Full Text] [Related]
17. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
18. CHEK2 mutations and the risk of papillary thyroid cancer.
Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
[TBL] [Abstract][Full Text] [Related]
19. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.
AlDubayan SH; Pyle LC; Gamulin M; Kulis T; Moore ND; Taylor-Weiner A; Hamid AA; Reardon B; Wubbenhorst B; Godse R; Vaughn DJ; Jacobs LA; Meien S; Grgic M; Kastelan Z; Markt SC; Damrauer SM; Rader DJ; Kember RL; Loud JT; Kanetsky PA; Greene MH; Sweeney CJ; Kubisch C; Nathanson KL; Van Allen EM; Stewart DR; Lessel D;
JAMA Oncol; 2019 Apr; 5(4):514-522. PubMed ID: 30676620
[TBL] [Abstract][Full Text] [Related]
20. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
Stubbins RJ; Korotev S; Godley LA
Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
